Home >  Urology >  Urology News >  FDA approves first drug...

FDA approves first drug for PET imaging of suspected prostate cancer metastasis

Written By :  Hina Zahid
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-12-02 04:15 GMT   |   Update On 2020-12-02 08:44 GMT
Advertisement

The FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11), a drug for PET imaging of prostate-specific membrane antigen (PSMA) positive levels in men with suspected prostate cancer metastasis, who may be curable by surgery or radiation therapy.

Ga 68 PSMA-11, which can also be used for patients with suspected prostate cancer recurrence, based on PSA levels, is a radioactive diagnostic agent given via intravenous injection. The drug can help determine treatment decisions, and spare individuals from unnecessary surgery.

"Ga 68 PSMA-11 is an important tool that can aid health care providers in assessing prostate cancer," said Alex Gorovets, MD, acting deputy director of the Office of Specialty Medicine in FDA's Center for Drug Evaluation and Research, in a statement.
GA 68 PSMA-11 binds to PSMA – an antigen that usually occurs in elevated levels for men with prostate cancer. The radioactive drug emits positrons and can be seen on a PET scan, thus indicating prostate cancer within the body.
Advertisement
The drug was evaluated in 2 prospective clinical trials, including a total of 960 men who each had 1 injection of Ga 68 PSMA-11. In the first trial, men with positive readings in their pelvic lymph nodes on Ga 68 PSMA-11 PET had a clinically meaningful rate of metastatic cancer that was confirmed by surgical pathology.
The second study involved patients with rising serum PSA levels after prostate surgery or radiotherapy. Nearly three-fourths (74%) had at least 1 positive cancer lesion detected by Ga 68 PSMA-11. Local recurrence or metastasis was confirmed in 91% of patients.
There were no major adverse events with Ga 68 PSMA-11. Common reactions included nausea, diarrhea, and dizziness. Additionally, clinicians should be aware that there is a risk of misdiagnosis if the agent binds to non-malignant cells.
"With this first approval of a PSMA-targeted PET imaging drug for men with prostate cancer, providers now have a new imaging approach to detect whether or not the cancer has spread to other parts of the body."
Tags:    
Article Source : BRIELLE BENYON

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Study identifies Urinary EGF as Protective Biomarker Against CKD Progression

Polygenic Risk Score Outperforms PSA and MRI in Detecting Clinically Significant Prostate Cancer: NEJM

Longer Antibiotic Therapy and Early PCN Drainage Linked to Better Outcomes in Urosepsis with Upper Ureteral Stones: Study

Enzyme-Loaded Magnetic Robots Offer Promising Noninvasive Solution for Kidney Stone Treatment: Study Shows

Ultrasound Screenings After UTI in Children May Miss Abnormalities if Limited to Under-2: Study Suggests

Inflammatory Blood Markers May Signal Severity of BPH Symptoms, New Study Finds

ESRD Significantly Increases Mortality in CDI Patients With IBD:Study

Bayer Nubeqa gets EU nod in third indication for advanced prostate cancer